Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

153
Pharmacies and Drug Stores Stock Outlook: Prospects Bright

7h zacks - 1
Over the past few years, an aging population, increasing wealth among the middle class, government focus on healthcare infrastructure and growing healthcare awareness have been driving the global retail pharmacy and drugstore industry. In North America, this industry has taken the shape of a multi-laired business, selling not just a range of prescription and over-the-counter medications but items such as wellness products and groceries.
BRK.A HLF RAD WBA LVS CVS AET WKL UNH

2
NVIDIA Gaming Drives the Deep Learning-AI Revolution

8h zacks
Our experts cut down 220 Zacks Rank #1 Strong Buys to the 7 most likely to jump in price immediately.
NVDA LVS

0
Business Services Outlook: Long-Term Picture Encouraging

8h zacks
Our experts cut down 220 Zacks Rank #1 Strong Buys to the 7 most likely to jump in price immediately.
LVS

51
BofA's Merrill Lynch to Pay $8.9M to Settle Regulatory Claim

9h zacks - 1
Bank of America Corporation’s (BAC - Free Report) unit Merrill Lynch has agreed to pay nearly $8.9 million to settle charges claimed by a U.S. regulator. The charges relate to the unit failing to disclose a conflict of interest with a third-party product provider, according to the Securities and Exchange Commission. Per the SEC, BofA’s brokerage unit exploited accounts of nearly 1,500 investors, who had about $575 million invested in products managed by the subsidiary of a foreign advisory firm.
BAC AMP BAC LAZ LVS AB

7
Is Celgene Set to See Improved Results in the Second Half?

9h zacks
Shares of Celgene Corporation (CELG - Free Report) have gained 18.6% in the last three months compared with growth of 4.3% for the industry.
XLRN CELGZ JUNO BLUE CELG BLUE LVS

100
Follow Constellation Brands, Bet Big on Cannabis ETFs

9h zacks - 1
Taking a few hits off a joint is no more a hush-hush thing as the marijuana industry is getting official approval from many regions for recreational uses, on top of medical usage. In any case, the medical marijuana industry has been growing by leaps and bounds lately and amassing investors’ interest.
STZ.B TWMJF ACB WEED ACBFF STZ LVS CGC

23
Intel (INTC) Stock Climbed Tuesday: Time to Buy?

9h zacks
Shares of Intel (INTC - Free Report) jumped as high as 2.7% on Tuesday to help buck a rather negative trend that has persisted since former CEO Brian Krzanich was forced out back in June. The question is what had investors excited about Intel? Plus, we will take a look to see if INTC stock is worth buying at the moment (hint: It might be just because it looks so cheap).
AMD LVS INTC

1
Alibaba and 4 Other Top Earnings Charts for the Week

9h zacks
There are over 150 companies reporting this week including many of the top retailers but there are still a few top technology names among them.
ADSK LB LVS HPQ

2
3 Tech Stocks for Dividend Investors to Buy Now

10h zacks
Tech stocks have been unpredictable at times recently, but the sector has rebounded from volatility strongly, and there is no question that tech has been the leader of the market’s strong multiyear run. However, this might mean that income investors—those focused on finding companies with solid dividends—might be feeling left out, as tech stocks aren’t really known for their payouts.
TXN GRMN NTAP LVS

5
Amazon Roundup: Walmart Challenge, India, UK, Germany, Ads, Drama

10h zacks
The last few weeks have seen big change in Amazon (AMZN - Free Report) World, with a changing competitive landscape, strengthening of key rival Walmart (WMT - Free Report) , new growth initiatives by the company and continued tightening of regulatory standards in Europe. Though it all, it remained a key innovator, pursuing opportunities like a very young company. Here are some of the high points-
GOOGL 532638 LVS WMT EBAY SHOPERSTOP

3
Robust Traffic Aids TJX Companies (TJX) Q2 Earnings, View Up

11h zacks
The TJX Companies, Inc. (TJX - Free Report) raised its guidance for fiscal 2019, after posting solid results for the second quarter. During the quarter, both earnings and revenues improved year over year on the back of continued improvements in customer traffic. We note this Zacks Rank #2 (Buy) stock has gained 34.2% in the past six months, while the industry rallied 17.6%.
DLTR TJX TGT LVS BIG

8
ETFs in Focus on GICS Changes: Top Tech & FANG

11h zacks
S&P Dow Jones and MSCI announced major changes in the Global Industry Classification Standard (GICS) last year, which will take place on September 28, after market close.
VGT STT FB GOOGL AAPL NFLX MSFT LVS

9
Keep an Eye on These ETF Areas as US & China Plan Trade Meet

11h zacks
Trade tensions between the United States and China have hit a fever pitch. On Aug 8, China announced 25% tariffs on U.S. imports worth another $16 billion in retaliation to the taxes to be imposed on an equal amount of imports by U.S. authorities starting Aug 23. The targeted commodities include crude oil, diesel, cars and coal.
MU BOE AMAT XTH XOP LVS QCOM INTC BA ITA CARZ

0
Editorial: Should U.S. Companies Report Earnings Only Twice a Year?

12h zacks
Last Friday, President Trump took to Twitter to make public his opinion that public companies should report result only twice a year instead of quarterly. He called on the SEC to investigate changing the reporting requirement.
LVS

20
Should You Buy Alibaba (BABA) Stock Ahead of Earnings?

12h zacks
Shares of Alibaba (BABA - Free Report) have slipped nearly 9% over the last three months as investors assess what impact trade tensions will have on the Chinese e-commerce powerhouse. With that said, Alibaba stock has climbed heading into the release of its quarterly financial results Thursday. So let’s see if BABA might be worth buying ahead of earnings.
JD MSFT SBUX LVS WMT

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 517834107